Image Credit: Vanessa Corral Photography
A measurable shift is underway in aesthetic medicine, one that Lisa Moody, founder of Skinwerx, is closely attuned to. Procedure volumes have continued to rise, yet more notably, Moody notes, patient preference has slowly moved toward treatments that prioritize longevity and tissue quality. Within that shift, she believes biosimulators are at the crux of that transition, which reflects a bigger change in how outcomes are defined.
Moody observed how that demand has accelerated sharply over the past two years, driven by both increased awareness and evolving patient expectations. “Patients now are asking for structural improvement that develops over time and integrates naturally with the body. And biostimulators are where that’s going,” she says.
Studies have shown that biostimulators have the potential to enhance dermal thickness, improve hydration, and contribute to facial rejuvenation and structural support. At a clinical level, Moody explains that biostimulators operate through a fundamentally different mechanism than traditional fillers. Instead of placing volume directly, they stimulate the body’s own regenerative processes, triggering a controlled inflammatory response, specifically collagen and elastin production, which may result in gradual but sustained improvement in skin integrity.
“It’s like putting fertilizer into the skin,” Moody adds. “You’re encouraging your body to grow its own collagen and elastin, so you’re rebuilding tissue from the inside out.”
This regenerative approach, Moody believes, aligns more closely with how patients want to age today. She points out that subtlety, longevity, and skin quality have become more valuable than immediate transformation, particularly among patients who are increasingly informed about treatment options.
According to Moody, this shift is also being accelerated by external factors, including widespread physiological changes seen in patients over the past few years. These changes have created a greater need for treatments that restore foundational tissue rather than simply augment it. “We’ve seen an explosion in interest, and increasing education and accessibility have played a significant role in normalizing the category,” she explains.
Moody explains that biostimulators are typically administered across a series of sessions, spaced over several months, to allow collagen production to build progressively, which aligns with the growing long-term mindset. This pacing, she notes, requires practitioner discipline and patient understanding. “You have to respect the process,” she explains. “You’re not chasing instant change, you’re allowing your body to do what it’s designed to do.”
She also highlights the strategic role biostimulators play within a broader aesthetic plan. “They aren’t replacing traditional treatments; they function as a foundational layer that supports and extends results over time,” Moody explains. Within her own practice, she often integrates them alongside other modalities to facilitate immediate refinement and stability. “I tell patients to think of it as protecting their investment. You can create structure today, but if you want that to hold over time, you need to rebuild the foundation underneath it,” she adds.
Versatility is another factor contributing to their rise. Moody points out that biostimulators can be applied across multiple areas, addressing facial concerns, overall skin quality, and tissue health. This aligns with her broader belief in holistic treatment philosophy. She explains, “People are starting to find solutions that look at the cohesive problem. They don’t want something that just treats one area anymore.”
Despite growing popularity, Moody acknowledges that misconceptions still exist, particularly rooted in earlier versions of the treatment. She highlights that advancements in technique, dilution, and training have significantly improved both predictability and outcomes, making the treatment more accessible to practitioners and patients alike.
Education, in her view, is the defining variable.
“It’s not enough for one person to know how to do it,” Moody says. “Your entire team has to understand the ‘why’ behind what you’re doing.”
At Skinwerx, Moody has built that philosophy into the operational model to allow expertise to be distributed across the team instead of gatekeeping it. She believes this may not only improve patient experience but also support the long-term evolution of the industry itself.
Moody further notes that biostimulators are becoming an essential skill set for modern practitioners, given their adaptability and alignment with regenerative medicine trends. What was once considered highly specialized is now, in her view, foundational. “We used to think it was so coveted, but it’s the most basic necessity today,” she says.
Patient outcomes reinforce that position. Moody reflects on cases where gradual collagen regeneration has led to meaningful, lasting improvements in appearance as well as in how patients perceive their own skin health over time. “It’s a different kind of result,” she explains. “People don’t always notice it overnight, but then one day they realize their skin feels stronger, looks healthier, and just holds itself better.”
As aesthetic procedures seep into fundamental routines, Moody believes that biostimulators are the forefront of that shift, representing a broader need toward treatments that work with the body’s natural processes. “The future of aesthetics is about working with the body, not around it,” she says. “Biostimulators are a big part of that conversation.”
